Sanofi (SNY) Shares Sold by Profund Advisors LLC
Profund Advisors LLC trimmed its holdings in shares of Sanofi (NYSE:SNY) by 21.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,776 shares of the company’s stock after selling 7,788 shares during the quarter. Profund Advisors LLC’s holdings in Sanofi were worth $1,379,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in SNY. Bank of New York Mellon Corp lifted its position in shares of Sanofi by 1.0% during the first quarter. Bank of New York Mellon Corp now owns 305,326 shares of the company’s stock worth $13,816,000 after purchasing an additional 3,013 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in shares of Sanofi by 69.8% in the first quarter. BNP Paribas Arbitrage SA now owns 17,692 shares of the company’s stock valued at $801,000 after acquiring an additional 7,275 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Sanofi by 8.0% in the first quarter. Ameriprise Financial Inc. now owns 495,865 shares of the company’s stock valued at $22,421,000 after acquiring an additional 36,873 shares in the last quarter. Eagle Asset Management Inc. bought a new stake in shares of Sanofi in the first quarter valued at about $260,000. Finally, Lockheed Martin Investment Management Co. bought a new stake in shares of Sanofi in the first quarter valued at about $6,303,000. Institutional investors and hedge funds own 9.33% of the company’s stock.
Several research firms recently weighed in on SNY. BidaskClub downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Friday, June 9th. Argus lifted their price objective on Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 9th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a report on Friday, June 2nd. HSBC Holdings plc upgraded Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company’s stock. Sanofi currently has an average rating of “Hold” and a consensus target price of $54.00.
Shares of Sanofi (NYSE SNY) opened at 49.10 on Wednesday. The stock’s 50 day moving average price is $48.38 and its 200-day moving average price is $47.45. Sanofi has a 52 week low of $36.81 and a 52 week high of $50.24. The stock has a market cap of $123.32 billion, a price-to-earnings ratio of 11.45 and a beta of 0.88.
Sanofi (NYSE:SNY) last issued its earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, hitting the consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The business had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. Equities analysts anticipate that Sanofi will post $3.34 earnings per share for the current fiscal year.
In other Sanofi news, major shareholder Sanofi bought 60,595 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The shares were acquired at an average price of $478.98 per share, with a total value of $29,023,793.10. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 1.00% of the stock is currently owned by company insiders.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.